The crisis also hurt revenue: The maker of genome sequencing systems saw a slowdown in business as some customers temporarily closed labs, and as a result, delayed testing using Illumina's tools.As the crisis abated, volumes increased in China, but the slowdown then moved through other regions such as Europe and the U.S. Illumina reported a 25% year-over-year drop in first-quarter total sequencing systems revenue to $79 million due to coronavirus disruptions.